 Accordingly, this national, multi-centre, open-label, single-arm phase II trial aims to investigate a truly metronomic schedule with daily oral vinorelbine in HRHER2-patients with metastatic breast cancer resistant to endocrine therapy, by assessing efficacy and safety. Oral vinorelbine will be administered at a daily dose of 30 mg flat dose without any adaptation to body weight or body surface area without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patients refusal or investigators decision to stop the treatment. 